Bipolar disorder is challenging to diagnose in children and adolescents, yet timely and accurate diagnosis is crucial. 

In this episode, we will discuss why assessment discrepancies arise, how we can manage them, and what these discrepancies tell us about a patient’s symptoms and response to treatment.

Every patient and family you see is inescapably impacted by weight stigma or fat shaming and the damage from this bias can lethal.

Nine years after DSM-5, Avoidant Restrictive Food Intake Disorder (ARFID) is still settling into clinical practice. Dr. Jennifer Thomas helps sort out the differential diagnosis between ARFID, anorexia, and other conditions and plan treatment in the context of comorbid conditions, such as anxiety disorders and Autism Spectrum Disorder.

Second-generation antipsychotics routinely breach the FDA’s level of concern of >7% body weight gain. This article examines the efficacy and safety of using off-label medications, such as metformin, to manage this side effect.

With the recent approval of another non-stimulant ADHD medication (viloxazine, brand name Qelbree), this is a good time to revisit atomoxetine.

The validity of bipolar disorder in children and adolescents has long been debated, and the history surrounding this diagnosis is controversial to say the least. In this podcast, we will discuss the evidence supporting whether bipolar disorder presents in youth, and how clinicians can best assess this disorder.

When patients are not amenable to usual therapy, equine-assisted psychotherapy (EAP) might be a good option. In this podcast, we’ll talk about working with horses as an alternative to, or in conjunction with, traditional therapy.